Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Gianluca Bossi"'
Autor:
Valentina Piastra, Federica Ganci, Andrea Sacconi, Angelina Pranteda, Matteo Allegretti, Roberta Bernardini, Martina Serra, Barbara Lupo, Emanuela Dell’Aquila, Gianluigi Ferretti, Edoardo Pescarmona, Armando Bartolazzi, Giovanni Blandino, Livio Trusolino, Gianluca Bossi
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-18 (2024)
Abstract Background Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer-related deaths worldwide, with a survival rate near to 10% when diagnosed at an advanced stage. Hence, the identification of ne
Externí odkaz:
https://doaj.org/article/536b2932e0ac43d4922bd78ef035bbe1
Autor:
Angelina Pranteda, Valentina Piastra, Martina Serra, Roberta Bernardini, Federica Lo Sardo, Silvia Carpano, Maria Grazia Diodoro, Armando Bartolazzi, Michele Milella, Giovanni Blandino, Gianluca Bossi
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 167, Iss , Pp 115480- (2023)
Colorectal cancer (CRC) patients with BRAF mutations develop resistance to BRAF inhibitors at a very early stage. Understanding the molecular mechanisms involved in BRAF inhibitor resistance is critical for the development of novel therapeutic opport
Externí odkaz:
https://doaj.org/article/9d7b8cc690a34230a359df41b031e9c8
Autor:
Rossella Loria, Valentina Laquintana, Stefano Scalera, Rocco Fraioli, Valentina Caprara, Italia Falcone, Chiara Bazzichetto, Marta Di Martile, Laura Rosanò, Donatella Del Bufalo, Gianluca Bossi, Isabella Sperduti, Irene Terrenato, Paolo Visca, Silvia Soddu, Michele Milella, Gennaro Ciliberto, Rita Falcioni, Virginia Ferraresi, Giulia Bon
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-18 (2022)
Abstract Background Despite the promise of dual BRAF/MEK inhibition as a therapy for BRAF-mutant (BRAF-mut) melanoma, heterogeneous responses have been observed in patients, thus predictors of benefit from therapy are needed. We have previously ident
Externí odkaz:
https://doaj.org/article/ab827d306d054785a82dd587f4b896b6
Autor:
Anna Giovanetti, Raffaella Marconi, Noha Awad, Hala Abuzied, Neveen Agamy, Mohamed Barakat, Cecilia Bartoleschi, Gianluca Bossi, Marco Canfora, Amr A. Elsaid, Laura Ioannilli, Horeya M. Ismail, Yasmine Amr Issa, Flavia Novelli, Maria Chiara Pardini, Claudio Pioli, Paola Pinnarò, Giuseppe Sanguineti, Mohamed M. Tahoun, Riccardo Turchi, Lidia Strigari
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract A radiological or nuclear attack could involve such a large number of subjects as to overwhelm the emergency facilities in charge. Resources should therefore be focused on those subjects needing immediate medical attention and care. In such
Externí odkaz:
https://doaj.org/article/be93ec5ae01f4b50af6c327db90398f8
Autor:
Anna Tesei, Chiara Arienti, Gianluca Bossi, Spartaco Santi, Ilaria De Santis, Alessandro Bevilacqua, Michele Zanoni, Sara Pignatta, Michela Cortesi, Alice Zamagni, Gianluca Storci, Massimiliano Bonafè, Anna Sarnelli, Antonino Romeo, Carola Cavallo, Armando Bartolazzi, Stefania Rossi, Antonella Soriani, Lidia Strigari
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-15 (2021)
Abstract Background Recent developments in abscopal effect strongly support the use of radiotherapy for the treatment of metastatic disease. However, deeper understanding of the molecular mechanisms underlying the abscopal effect are required to best
Externí odkaz:
https://doaj.org/article/293f7adfae644ac49b5cfa53c916e022
Autor:
Lorenzo Stramucci, Gianluca Bossi
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-3 (2019)
Abstract MKK3 is a member of the dual specificity kinase group specific upstream activator of p38 MAPK proteins. We originally identified MKK3 as mutant p53 (mutp53) gain-of-function (GOF) upregulated target gene in different tumor models. To deeply
Externí odkaz:
https://doaj.org/article/9cf277f638ad46eabeaf84c3f038a59c
Autor:
Rossella Loria, Claudia Giliberti, Angelico Bedini, Raffaele Palomba, Giulio Caracciolo, Pierpaolo Ceci, Elisabetta Falvo, Raffaella Marconi, Rita Falcioni, Gianluca Bossi, Lidia Strigari
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-11 (2019)
Abstract Background The possibility to combine Low Intensity UltraSound (LIUS) and Nanoparticles (NP) could represent a promising strategy for drugs delivery in tumors difficult to treat overcoming resistance to therapies. On one side the NP can carr
Externí odkaz:
https://doaj.org/article/cfebdae6934646d2bc7d0ec2ba8f95dd
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0171559 (2017)
BACKGROUND:Preclinical in vivo studies using small animals are considered crucial in translational cancer research and clinical implementation of novel treatments. This is of paramount relevance in radiobiology, especially for any technological devel
Externí odkaz:
https://doaj.org/article/7fd652dbd75c456880bd2f4c591fff1b
Autor:
Luca Madaro, Andrea Pelle, Carmine Nicoletti, Annunziata Crupi, Valeria Marrocco, Gianluca Bossi, Silvia Soddu, Marina Bouché
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e31515 (2012)
Inflammation is a key pathological characteristic of dystrophic muscle lesion formation, limiting muscle regeneration and resulting in fibrotic and fatty tissue replacement of muscle, which exacerbates the wasting process in dystrophic muscles. Limit
Externí odkaz:
https://doaj.org/article/3024fa5358b4464cb40896d33a9f2f7b
Autor:
Bianca M. Zani, Richard G. Pestell, Ada Sacchi, Agnese Di Rocco, Carmela Ciccarelli, Gianluca Bossi, Francesco Marampon
Supplementary Fig. S1 from MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af221fd141689f1a83d9551bfb741471
https://doi.org/10.1158/1535-7163.22484921.v1
https://doi.org/10.1158/1535-7163.22484921.v1
